TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05837208

Intervention type: OTHER
Intervention: RV4369A cosmetic product
Description: The product is applied 1 or 2 times during the 2 study visits. The product is recovered by the technician after application of the product by the volunteer.~Application modalities:~Inclusion Assessment: The study product is given to the volunteer who applies it to his face (forehead) according to his usual habits.~After a waiting time and Multispectral camera measurements, the study product is again applied by the volunteer to his face according to his usual habits.~Final assessment: The study product is applied by the Clinical Research Technician on the subject's forearm on 4 delimited areas at specific quantities.~After a waiting period and Multispectral camera measurements on the forearm areas, the study product is given to the volunteer who applies it on his face according to the recommendations of use provided by the Technician.
Study: NCT05222464

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care treatments
Description: Interventions will consist of 4 classes of standard of care treatments, namely, lifestyle modifications, complementary and alternative medicine (CAM) therapies, prescription medications, or adjustment of anti-cancer therapy.
Study: NCT06210906

Intervention type: OTHER
Intervention: Assessment of gastric volume
Description: Gastric volume is assessed using ultrasound.

Intervention type: OTHER
Intervention: Assessment of gastric volume
Description: Gastric volume is assessed using ultrasound.
Study: NCT05272384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT05511532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthopaedic treatment
Description: Female and male patients aged between 6 and 12 years are included in the study. Initially, the values of dorsiflexion of the tibio-fibular-talar joint and dorsiflexion of the first metatarsophalangeal joint will be measured to rule out hallux rigidus and ankle equinus, respectively.~Those patients who do not present hallux rigidus or equinus ankle, will be included in the study and will have their computerized foot pressures taken.
Study: NCT06258720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF82422
Description: Lu AF82422 solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF82422
Description: Lu AF82422 solution for intravenous infusion
Study: NCT05793450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: 2.0mg, SC, single dose
Study: NCT05933083

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person cardiac rehabilitation
Description: In-person exercise training, health education, and counseling
Study: NCT05793450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: 2.0mg, SC, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: 2.0mg, SC, single dose
Study: NCT05284708

Intervention type: DEVICE
Group type: OTHER
Intervention: Atalante
Description: Powered Exoskeleton
Study: NCT06308302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A (Inspiratory Muscles Training + Aerobic Interval Training)
Description: Performed Inspiratory muscle training on a breather device (20), (10 inhales with maximum 3-sec hold), 3 sets with a 1-minute interval between each set, for 6 days a week along with aerobic interval training on alternate days (3 days a week for 20-25 minutes in 1st week, 30-35 minutes in 2nd week, 40 minutes in 3rd week, 45-60 minutes in 4th week each session). (120)~Baseline treatment given is Aerobic interval training and COPD medications.
Study: NCT04871984

Intervention type: DEVICE
Intervention: Ureteroscopy for upper tract stone treatment with Holmium laser
Description: Rigid or flexible ureteroscopy for ureteral or renal stone. Lithotripsy with Holmium laser

Intervention type: DEVICE
Intervention: Ureteroscopy for upper tract stone treatment with Thulium laser
Description: Rigid or flexible ureteroscopy for ureteral or renal stone. Lithotripsy with Thulium laser
Study: NCT06308302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B (Expiratory Muscles Training +Aerobic Interval Training)
Description: Performed Expiratory muscle training along with aerobic interval training on alternate days (3 days a week for 20-25 minutes in 1st week, 30-35 minutes in 2nd week, 40-45 minutes in 3rd week, 45-60 minutes in 4th week per session). (120)~Baseline treatment given is Aerobic interval training and COPD medications.
Study: NCT05721872

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: D-isoascorbic Acid (D-VC) With Arsenic Trioxide (ATO)
Description: After 2 hours of intravenous administration of arsenic trioxide (ATO) (at a dose of 0.15 mg / kg / day) participants will further receive D-isoascorbic acid (D-VC) intravenously once a day at the maximum tolerated dose, determined at the end of phase I.~Phase 1 - Scheme 1 - single intravenous administration in monotherapy with dose escalation (0.05, 0.1, 0.15 g/kg/day); Scheme 2 - single intravenous administration in the mode of sequential administration with arsenic trioxide with dose escalation of D-isoascorbic acid (0.05, 0.1, 0.15 g/kg/day).~Phase 2 - Study group 1: After 2 hours of intravenous administration of arsenic trioxide (ATO) (at a dose of 0.15 mg / kg / day) participants will further receive D-isoascorbic acid (D-VC) intravenously once a day at the maximum tolerated dose, determined at the end of phase I for at least 15 patients.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: D-isoascorbic Acid (D-VC) With Arsenic Trioxide (ATO)
Description: After 2 hours of intravenous administration of arsenic trioxide (ATO) (at a dose of 0.15 mg / kg / day) participants will further receive D-isoascorbic acid (D-VC) intravenously once a day at the maximum tolerated dose, determined at the end of phase I.~Phase 1 - Scheme 1 - single intravenous administration in monotherapy with dose escalation (0.05, 0.1, 0.15 g/kg/day); Scheme 2 - single intravenous administration in the mode of sequential administration with arsenic trioxide with dose escalation of D-isoascorbic acid (0.05, 0.1, 0.15 g/kg/day).~Phase 2 - Study group 1: After 2 hours of intravenous administration of arsenic trioxide (ATO) (at a dose of 0.15 mg / kg / day) participants will further receive D-isoascorbic acid (D-VC) intravenously once a day at the maximum tolerated dose, determined at the end of phase I for at least 15 patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX/FOLFIRI regimen
Description: FOLFOX - oxaliplatin 85mg/m2 1 day Leucovorin 200mg/m2 IV 2h, 1, 2 days 5 - Fluorouracil 400mg/m2 IV bolus, 1, 2 days 5 - Fluorouracil 600mg/m2 IV 22h, 1, 2 days~FOLFIRI Irinotecan 180 mg/m2 IV Leucovorin 400 mg/m2 IV Fluorouracil bolus 400 mg/m2 IV Fluorouracil infusional 2400 mg/m2 IV Courses are held every 2 weeks
Study: NCT06480721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical management based on the index MRI and an additional [¹⁸F] FET PET scan
Description: Patients in the investigational arm will undergo the extra FET-PET scan, with use of the O-(2-~¹⁸F-fluoroethyl)-L-tyrosine (¹⁸F-FET) tracer. FET-PET scanning will be performed according to the joint European Association of Nuclear Medicine (EANM)/European Association of Neuro-Oncology (EANO)/Response Assessment in Neuro-oncology (RANO) guidelines. In most patients, a static scan (20-40 minutes post-injection) will performed. If the logistics of the research site allow for a dynamic scan (0-60 minutes post-injection), this will be performed. Interpretation will be done by an experienced nuclear medicine physician from the local center according to current European guidelines. Central review will be performed by a panel of nuclear medicine physicians from the study team. Clinical management is based on the index MRI and this additional \[¹⁸F\] FET PET scan.
Study: NCT04581109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Twenty ml of blood will be drawn from each patient : 10 ml of blood will be drawn on CellSave tubes (fixed cells) for CTC detection using the FDA-cleared CellSearch system (gold standard) and 10 ml of blood will be drawn on EDTA tubes (viable cells) for the detection of functional CTCs using the EPIDROP.
Study: NCT05448417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive high-frequency oscillatory ventilation
Description: Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive Bilevel Positive Pressure Ventilation
Description: Noninvasive Bilevel Positive Pressure Ventilation
Study: NCT05474521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CODTimer test
Description: The Illinois test times of the participants will be measured with different phone applications that measure the change of direction performance, and each individual will perform the test twice.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CODTimer test
Description: The Illinois test times of the participants will be measured with different phone applications that measure the change of direction performance, and each individual will perform the test twice.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CODTimer test
Description: The Illinois test times of the participants will be measured with different phone applications that measure the change of direction performance, and each individual will perform the test twice.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CODTimer test
Description: The Illinois test times of the participants will be measured with different phone applications that measure the change of direction performance, and each individual will perform the test twice.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CODTimer test
Description: The Illinois test times of the participants will be measured with different phone applications that measure the change of direction performance, and each individual will perform the test twice.
Study: NCT06512207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate + Sintilimab
Description: Leuprolide, an FDA-approved GnRH agonist, reduces sex hormone production and is widely used in clinical practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: PD-1 inhibitor
Study: NCT05351879

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GAD-alum (Diamyd) 40 μg/mL
Description: Recombinant Human Glutamic Acid Decarboxylase (rhGAD65) adsorbed to Alhydrogel at a concentration of 40 μg/mL and is given as a sterile solution for intralymphatic injection
Study: NCT05949047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Emotion Regulation Training via Psychological Distancing
Description: The project will randomly assign Alzheimer's Disease or related dementia (AD/ADRD) unpaid primary caregivers to receive a brief course of reappraisal training using either psychological distancing or reinterpretation, or to a no regulation natural history control condition. In the Psychological Distancing group, participants will be asked to down-regulate negative emotion by reappraising an emotional stimulus as an objective, impartial observer.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Emotion Regulation Training via Reinterpretation
Description: The project will randomly assign Alzheimer's Disease or related dementia (AD/ADRD) unpaid primary caregivers to receive a brief course of reappraisal training using either psychological distancing or reinterpretation, or to a no regulation natural history control condition. In the Reinterpretation group, participants will be asked to down-regulate negative emotion by imagining a better outcome (when engaging with an emotional stimulus) than what initially seemed apparent.
Study: NCT05474521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CODTimer test
Description: The Illinois test times of the participants will be measured with different phone applications that measure the change of direction performance, and each individual will perform the test twice.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CODTimer test
Description: The Illinois test times of the participants will be measured with different phone applications that measure the change of direction performance, and each individual will perform the test twice.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CODTimer test
Description: The Illinois test times of the participants will be measured with different phone applications that measure the change of direction performance, and each individual will perform the test twice.
Study: NCT06441838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surah Inshirah
Description: The effects of Surah Al-Inshirah on patients' depression, anxiety, stress and mental well-being will be evaluated during hemodialysis in the experimental group.
Study: NCT05657197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: A 12-week exercise program consisting of three times per week 1-hour sessions, including 30-minutes aerobic- and 30-minutes progressive resistance training. The intensity of training will be adjusted to each individual, based on a cardiopulmonary exercise test. Training sessions will be performed in groups of 10 participants under supervision of a sports physical therapist.
Study: NCT06040034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: Lidocaine given as bolus or continuous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: Lidocaine given as bolus or continuous infusion.
Study: NCT06129201

Intervention type: OTHER
Intervention: Tongue image
Description: Using intelligent imaging devices to collect subject tongue images

Intervention type: OTHER
Intervention: Tongue image
Description: Using intelligent imaging devices to collect subject tongue images
Study: NCT05297890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Dosage Form: Lorlatinib tablet, Dosage: 25mg/tablet, Dosing Regimens: 100mg, oral, Quaque Die (QD), continuous administration in 21 days as a cycle
Study: NCT05657197

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care, including general advice concerning chronic fatigue.
Study: NCT05844176

Intervention type: OTHER
Intervention: Routine clinical treatment
Description: Routine clinical treatment is based on the latest international and local guidelines

Intervention type: OTHER
Intervention: Routine clinical treatment
Description: Routine clinical treatment is based on the latest international and local guidelines
Study: NCT02100995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Simultaneously Targeting Obesity and Pain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss/Weight Self-Management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Pain Self-Management
Study: NCT05263856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: The parameter setting of 810nm wavelength laser acupuncture device in 1) ear were irradiated with a 4mm probe, adjusted to Nogier A frequency for acute treatment, and the pulsed mode was irradiated with an emission frequency of 200mW for 10seconds, each acupoint provided 1 joule of energy with total of 12joules,and 2) myofascial trigger point were irradiated with a 10mm probe, adjusted to Nogier C frequency for muscle treatment, and the pulsed mode was irradiated with an emission frequency of 500mW for 20 seconds, each acupoint provided 5 joule of energy with total of 50 joules, providing a total of 62 joules of one intervention session.
Study: NCT05981261

Intervention type: OTHER
Group type: OTHER
Intervention: inducement of experimental pain
Description: Inducement of experimental pain
Study: NCT04072393

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation
Description: -Patients will be evaluated by the clinical team at The Heart Care Institute (HCI). They will receive a heart rate monitor, blood pressure monitor, and weight scale that they will take home with them. They will receive training on how to use the heart rate monitor and blood pressure monitor. They will receive training on how to record their exercises and weights in the teleHeart application by an exercise physiologist from HCI. Within 6 weeks of completion of standard of care radiation therapy or cytotoxic chemotherapy (whichever is last), they will be prescribed a course of home-based CR by a cardiologist at HCI and be instructed on the regimen by an exercise physiologist from HCI.
Study: NCT06338917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity physical activity program
Description: The intervention group will participate in a vigorous-intensity physical activity program which pretends to increase the number of physical activity daily bouts that people with severe mental illness practice. The main aim is to achieve the basic physical activity practice guidelines of World Health Organization, which means achieve to do 75-150 minutes per week of moderate-to-high intensity physical activity.
Study: NCT06022276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nitozumab injection 400mg/cycle, every 21 days/cycle, until disease progression, intolerable toxicity or death, or subject decision to withdraw from the study.The molecular testing results of the patient are analyzed and interpreted by the MTB team, and appropriate combination therapy(Nitozumab+) strategies are proposed based on the patient's previous treatment history, physical condition, drug accessibility, and economic status.
Study: NCT04722510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repeated transcranial magnetic stimulation
Description: Transcranial magnetic stimulation is a non-invasive brain modulation technique that has proven to be a useful study and treatment tool in neuropsychiatric disorders. This technique allows to increase (with high frequency protocol, \> 1 Hz) or decrease (with low frecuency protocols, 1 hz or less) neuronal excitability in a focused cortical area.
Study: NCT04515706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod is an anti-rheumatic drug that approved for treating rheumatoid arthritis in East Asia. Recent data reveal its independent anti-fibrosis effect.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iguratimod
Description: Iguratimod is an anti-rheumatic drug that approved for treating rheumatoid arthritis in East Asia. Recent data reveal its independent anti-fibrosis effect.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Iguratimod
Study: NCT06581523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SKY Breath and Meditation
Description: SKY Breath and Meditation is a unique breath-based technique that uses cyclical, rhythmic patterns of breath to bring the mind and body effortlessly into meditation. It has been empirically validated and holds distinct advantages over other forms of meditation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SKY Breath and Meditation
Description: SKY Breath and Meditation is a unique breath-based technique that uses cyclical, rhythmic patterns of breath to bring the mind and body effortlessly into meditation. It has been empirically validated and holds distinct advantages over other forms of meditation.
Study: NCT05933083

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telehealth cardiac rehabilitation
Description: Telehealth exercise training, health education, and counseling
Study: NCT05161975

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin K2
Description: Volunteers will be randomly assigned to vitamin K2 or placebo group and consume one tablet of the food supplement per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K2
Description: Volunteers will be randomly assigned to vitamin K2 or placebo group and consume one tablet of the food supplement per day.
Study: NCT06438523

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PULPOTOMY OF MATURE PERMENANT TEETH
Description: Removal of coronal pulp and expose the orifices to apply the materials with aim to preserve vitality of remaining pulp

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PULPOTOMY OF MATURE PERMENANT TEETH
Description: Removal of coronal pulp and expose the orifices to apply the materials with aim to preserve vitality of remaining pulp

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PULPOTOMY OF MATURE PERMENANT TEETH
Description: Removal of coronal pulp and expose the orifices to apply the materials with aim to preserve vitality of remaining pulp
Study: NCT05799612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given by IV (vein)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA plus Lysate-loaded Dendritic Cell Vaccine
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGYLATED-INTERFERON ALPHA-2A
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given by IV (vein)
Study: NCT05918484

Intervention type: DEVICE
Intervention: Intermittenly scanned continuous glucose monitoring
Description: Use of Intermittenly scanned continuous glucose monitoring (FreeStyle Libre) and meeting the glycometric data criteria:~* Time in range 70-180 mg/L \>70%~* Glycemic management index \<7%~* Coefficient of variation \<36%

Intervention type: OTHER
Intervention: MODY genetic diagnostic test
Description: Those patients fulfilling the glycometric data criteria and with clinical MODY suspicion:~* diagnosis before 35 years of age~* first-degree family history of diabetes.~* negative pancreatic autoimmunity (Ac GAD, IA-2A and Ac ZnT8)~* preserved pancreatic beta cell function defined as C-peptide \> 0.2 ng/mL in the presence of plasma glycemia \>140 mg/dL).~Those patients who meet the previous criteria will proceed to the MODY genetic diagnostic test.
Study: NCT04630236

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound
Description: Using ultrasound control, the central vein catheter is injected with saline solution and the time to detect the saline bolus in the ultrasound is measured.
Study: NCT06525025

Intervention type: OTHER
Intervention: Observational study, non intervention
Description: Observational study, non intervention

Intervention type: OTHER
Intervention: Observational study, non intervention
Description: Observational study, non intervention

Intervention type: OTHER
Intervention: Observational study, non intervention
Description: Observational study, non intervention